Cancer Causes & Control

, Volume 21, Issue 5, pp 697–707 | Cite as

Parkinson’s disease and cancer risk: a systematic review and meta-analysis

  • Archna Bajaj
  • Jane A. Driver
  • Eva S. Schernhammer
Original Paper



To appraise the existing literature on cancer risk among patients with Parkinson’s disease (PD), determine the overall cancer risk ratio among patients with PD, explore reasons for variations in study results, and assess the potential for publication bias.


Studies reporting cancer risk in patients with PD were identified by searching electronic databases through 18 November 2009 using the terms PARKINSON DISEASE, NEOPLASM, and CANCER. Reviewers individually performed data extraction and scored each study using a quality assessment instrument. Cancer risk in all patients with PD was calculated overall, and after excluding melanoma and other skin cancers. We tested for heterogeneity and publication bias, and stratified for gender, smoking-related versus non-smoking-related cancers, and study quality. We pooled effect sizes using fixed-effects and random-effects models.


We included 29 studies in the overall analysis for a total of 107,598 patients with PD. Compared to controls, the aggregate risk for cancer in patients with PD was 0.73 (95% confidence interval [CI], 0.63–0.83), and after excluding skin tumors, 0.69 (95% CI, 0.62–0.78). These risks varied by gender (males, RR = 0.71, 95% CI, 0.57–0.88; females, RR = 0.82; 95% CI, 0.68–0.98). After strictly excluding skin tumors, both smoking-related (RR = 0.61; 95% CI, 0.58–0.65) and non-smoking-related cancer rates (RR = 0.76; 95% CI, 0.65–0.89) were significantly lower among patients with PD .


Studies on cancer risk among patients with PD collectively show significantly reduced cancer risk ratios. Further research to explain the biological mechanisms, particularly for the association with non-smoking-related cancers, appears warranted.


Neurodegenerative diseases Neoplasm Meta-analysis 


Conflict of interest statement

All authors declare no disclosures and no financial conflicts of interest.


  1. 1.
    Inzelberg R, Jankovic J (2007) Are Parkinson disease patients protected from some but not all cancers? Neurology 69(15):1542–1550CrossRefPubMedGoogle Scholar
  2. 2.
    West AB, Dawson VL, Dawson TM (2005) To die or grow: Parkinson’s disease and cancer. Trends Neurosci 28(7):348–352CrossRefPubMedGoogle Scholar
  3. 3.
    Staropoli JF (2008) Tumorigenesis and neurodegeneration: two sides of the same coin? Bioessays 30(8):719–727CrossRefPubMedGoogle Scholar
  4. 4.
    Driver JA, Logroscino G, Buring JE, Gaziano JM, Kurth T (2007) A prospective cohort study of cancer incidence following the diagnosis of Parkinson’s disease. Cancer Epidemiol Biomarkers Prev 16(6):1260–1265CrossRefPubMedGoogle Scholar
  5. 5.
    Olsen JH, Friis S, Frederiksen K (2006) Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 17(5):582–587CrossRefPubMedGoogle Scholar
  6. 6.
    Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, Moller H (2005) Atypical cancer pattern in patients with Parkinson’s disease. Br J Cancer 92(1):201–205CrossRefPubMedGoogle Scholar
  7. 7.
    Vanacore N, Spila-Alegiani S, Raschetti R, Meco G (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52(2):395–398PubMedGoogle Scholar
  8. 8.
    Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S (2007) Treatment with levodopa and risk for malignant melanoma. Mov Disord 22(9):1252–1257CrossRefPubMedGoogle Scholar
  9. 9.
    Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012CrossRefPubMedGoogle Scholar
  10. 10.
    D’Amelio M, Ragonese P, Morgante L, Reggio A, Callari G, Salemi G et al (2006) Long-term survival of Parkinson’s disease. J Neurol 253:33–37CrossRefPubMedGoogle Scholar
  11. 11.
    Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore DM, McDonnell SK et al (2005) Risk of cancer after the diagnosis of Parkinson’s disease: a historical cohort study. Mov Disord 20(6):719–725CrossRefPubMedGoogle Scholar
  12. 12.
    Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA (2006) Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord 21(4):446–455CrossRefPubMedGoogle Scholar
  13. 13.
    Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH (1995) Occurrence of different cancers in patients with Parkinson’s disease. BMJ 310(6993):1500–1501PubMedGoogle Scholar
  14. 14.
    Morgante L (2000) Parkinson disease survival: a population based study. Arch Neurol 57(4):507–512CrossRefPubMedGoogle Scholar
  15. 15.
    Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G (1998) Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 97(1):20–26PubMedGoogle Scholar
  16. 16.
    Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2007) Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson’s disease. Cancer Causes Control 18(7):705–711CrossRefPubMedGoogle Scholar
  17. 17.
    Elbaz A, Peterson BJ, Yang P, Van Gerpen JA, Bower JH, Maraganore DM et al (2002) Nonfatal cancer preceding Parkinson’s disease: a case-control study. Epidemiology 13(2):157–164CrossRefPubMedGoogle Scholar
  18. 18.
    Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G (2008) Parkinson disease and risk of mortality: a prospective comorbidity-matched cohort study. Neurology 70(16 pt 2):1423–1430CrossRefPubMedGoogle Scholar
  19. 19.
    Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson’s disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 44(10):1865–1868PubMedGoogle Scholar
  20. 20.
    Kondo K (1984) Motor neuron disease and Parkinson’s disease are not associated with other disorders at autopsy. Neuroepidemiology 3:182–194CrossRefGoogle Scholar
  21. 21.
    Marmot MG (1981) Mortality and Parkinson’s disease. In: Rose FC, Capildeo R (eds) Research progress in Parkinsons’ disease. Pitman Medical, Kent, pp 9–16Google Scholar
  22. 22.
    Pritchard PB III, Netsky MG (1973) Prevalence of neoplasms and causes of death in paralysis agitans. A necropsy study. Neurology 23(3):215–222PubMedGoogle Scholar
  23. 23.
    Levine RL, Jones JC, Bee N (1992) Stroke and Parkinson’s disease. Stroke 23(6):839–842PubMedGoogle Scholar
  24. 24.
    Di Rocco A, Molinari SP, Kollmeier B, Yahr MD (1996) Parkinson’s disease: progression and mortality in the l-DOPA era. Adv Neurol 69:3–11PubMedGoogle Scholar
  25. 25.
    Vital Statistics of the United States, 1963. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics; 1965Google Scholar
  26. 26.
    The health consequences of smoking: a report of the surgeon general. Atlanta, GA: Centers for Disease Control and Prevention, Office on Smoking and Health; 2004Google Scholar
  27. 27.
    Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Newton Lower Falls, Epidemiology Resources IncGoogle Scholar
  28. 28.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMedGoogle Scholar
  29. 29.
    Cochran WG (1954) Some methods for strengthening the common χ2 tests. Biometrics 10(4):417–451CrossRefGoogle Scholar
  30. 30.
    Takkouche B, Cadarso-Suarez C, Spiegalman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150:206–215PubMedGoogle Scholar
  31. 31.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101CrossRefPubMedGoogle Scholar
  32. 32.
    Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedGoogle Scholar
  33. 33.
    Stata commands for meta-analyses. STATA 2001. [online]. Available at:
  34. 34.
    Barbeau A, Joly JG (1963) Parkinson et cancer. Union Med Can 92:169–174PubMedGoogle Scholar
  35. 35.
    Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19(1):49–53CrossRefPubMedGoogle Scholar
  36. 36.
    Jansson B, Jankovic J (1985) Low cancer rates among patients with Parkinson’s disease. Ann Neurol 17(5):505–509CrossRefPubMedGoogle Scholar
  37. 37.
    Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S (2000) Mortality and cancer incidence in patients with Parkinson’s disease. J Neurol 247(6):429–434CrossRefPubMedGoogle Scholar
  38. 38.
    Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S et al (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60(1):87–93PubMedGoogle Scholar
  39. 39.
    Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ (2009) Cancer in patients with motor neuron disease, multiple sclerosis, and Parkinson’s disease: record-linkage studies. J Neurol Neurosurg PsychiatryGoogle Scholar
  40. 40.
    D’Amelio M, Ragonese P, Morgante L, Epifanio A, Callari G, Salemi G et al (2004) Tumor diagnosis preceding Parkinson’s disease: a case-control study. Mov Disord 19(7):807–811CrossRefPubMedGoogle Scholar
  41. 41.
    Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 12(3):185–189CrossRefPubMedGoogle Scholar
  42. 42.
    Rajput AH, Offord KP, Beard CM, Kurland LT (1987) A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson’s disease. Neurology 37(2):226–232PubMedGoogle Scholar
  43. 43.
    Ben-Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with Parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58(3):293–299CrossRefPubMedGoogle Scholar
  44. 44.
    Beyer MK, Herlofson K, Arsland D, Larsen JP (2001) Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 103(1):7–11CrossRefPubMedGoogle Scholar
  45. 45.
    Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK (2003) Survival time, mortality, and cause of death in elderly patients with Parkinson’s disease: a 9-year follow-up. Mov Disord 18(11):1312–1316CrossRefPubMedGoogle Scholar
  46. 46.
    Harada H, Nishikawa S, Takahashi K (1983) Epidemiology of Parkinson’s disease in a Japanese city. Arch Neurol 40(3):151–154PubMedGoogle Scholar
  47. 47.
    Hely MA, Morris JG, Traficante R, Reid WG, O’Sullivan DJ, Williamson PM (1999) The Sydney multicentre study of Parkinson’s disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 67(3):300–307CrossRefPubMedGoogle Scholar
  48. 48.
    Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442PubMedGoogle Scholar
  49. 49.
    Kessler II (1972) Epidemiologic studies of Parkinson’s disease. II. A hospital-based survey. Am J Epidemiol 95(4):308–318PubMedGoogle Scholar
  50. 50.
    Louis ED, Marder K, Cote L, Tang M, Mayeux R (1997) Mortality from Parkinson’s disease. Arch Neurol 54(3):260–264PubMedGoogle Scholar
  51. 51.
    Wermuth L, Stenager EN, Stenager E, Boldsen J (1995) Mortality in patients with Parkinson’s disease. Acta Neurol Scand 92(1):55–58PubMedCrossRefGoogle Scholar
  52. 52.
    Westlund K, Hougen A (1956) Cancer as a cause of death among patients with other chronic diseases. J Am Med Assoc 162:1003Google Scholar
  53. 53.
    SEER Cancer Statistics Review. 1975-2005. Natl Cancer Inst. [online]. Available at
  54. 54.
    Riggs JE (1999) Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 53(5):1158–1159PubMedGoogle Scholar
  55. 55.
    Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol 52:276–284CrossRefPubMedGoogle Scholar
  56. 56.
    McNaught KS, Perl DP, Brownell AL, Olanow CW (2004) Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol 56(1):149–162CrossRefPubMedGoogle Scholar
  57. 57.
    Montagut C, Rovira A, Albanell J (2006) The proteasome: a novel target for anticancer therapy. Clin Transl Oncol 8(5):313–317CrossRefPubMedGoogle Scholar
  58. 58.
    Schernhammer E, Chen H, Ritz B (2006) Circulating melatonin levels: possible link between Parkinson’s disease and cancer risk? Cancer Causes Control 17(4):577–582CrossRefPubMedGoogle Scholar
  59. 59.
    Zanetti R, Loria D, Rosso S (2006) Melanoma, Parkinson’s disease and levodopa: causal or spurious link? A review of the literature. Melanoma Res 16(3):201–206CrossRefPubMedGoogle Scholar
  60. 60.
    Fiala KH, Whetteckey J, Manyam BV (2003) Malignant melanoma and levodopa in Parkinson’s disease: causality or coincidence? Parkinsonism Relat Disord 9(6):321–327CrossRefPubMedGoogle Scholar
  61. 61.
    Cancer Statistics 2008, American Cancer Society. [online]. Available at:

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Archna Bajaj
    • 1
    • 2
  • Jane A. Driver
    • 3
    • 4
  • Eva S. Schernhammer
    • 1
    • 5
    • 6
  1. 1.Channing Laboratory, Department of MedicineBrigham and Women’s Hospital and Harvard Medical SchoolBostonUSA
  2. 2.Case Western Reserve University School of MedicineClevelandUSA
  3. 3.Division of Aging, Department of MedicineBrigham and Women’s HospitalBostonUSA
  4. 4.Geriatric Research, Education and Clinical CenterBoston VA Healthcare SystemBostonUSA
  5. 5.Department of EpidemiologyHarvard School of Public HealthBostonUSA
  6. 6.LBI-ACR-CTO & ACR-ITR VIEnna/CEADDPViennaAustria

Personalised recommendations